Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice
Autore:
Tonra, JR; Ono, M; Liu, XC; Garcia, K; Jackson, C; Yancopoulos, GD; Wiegand, SJ; Wong, V;
Indirizzi:
Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA Regeneron Pharmaceut Inc Tarrytown NY USA 10591 , Tarrytown, NY 10591 USA Sumitomo Pharmaceut Res Ctr, Discovery Labs 2, Osaka, Japan Sumitomo Pharmaceut Res Ctr Osaka Japan Discovery Labs 2, Osaka, Japan
Titolo Testata:
DIABETES
fascicolo: 3, volume: 48, anno: 1999,
pagine: 588 - 594
SICI:
0012-1797(199903)48:3<588:BNFIBG>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALANINE AMINOTRANSFERASE; SENSORY NEURONS; OBESE PATIENTS; TRK RECEPTORS; FATTY LIVER; FACTORS NGF; BETA-CELL; BDNF; NT-3; HEPATITIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Wong, V RegeneronAPharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY10591 US Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY USA 10591
Citazione:
J.R. Tonra et al., "Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice", DIABETES, 48(3), 1999, pp. 588-594

Abstract

Systemic administration of brain-derived neurotrophic factor (BDNF) decreases nonfasted blood glucose in obese, non-insulin-dependent diabetic C57BLKS-Lepr(db)/lepr(db) (db/db) mice, with a concomitant, decrease in body weight. By measuring percent HbA(1c) in BDNF-treated and pair-fed animals, we show that the effects of BDNF on nonfasted blood glucose levels are not caused by decreased food intake but reflect a significant improvement in blood glucose control. Furthermore, once established, this effect can persist forweeks after cessation of BDNF treatment. Oral glucose tolerance tests wereperformed to examine the effects of BDNF on blood glucose control in the fasted state and after an oral glucose challenge. BDNF treatment normalized fasting blood glucose from initially hyperglycemic levels and also showed evidence for beneficial, although less marked, effects on the ability to remove exogenous glucose from blood. One means to lower fasting blood glucose is to reduce the glucose output of peripheral tissues that normally play a part in the maintenance of fasting hyperglycemia. Because the liver is the major endogenous source of glucose in blood during fasting, and because hepatic weight: and glucose out-put are increased in type 2 diabetes, we evaluated the effects of BDNF on liver tissue. BDNF reduced the hepatomegaly present in db/db mice, in association with reduced liver glycogen and reduced liver enzyme activity in serum, supporting the possible involvement of liver tissue in the mechanism of action for BDNF.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/07/20 alle ore 22:26:38